Adipokines as therapeutic targets in breast cancer treatment

Expert Opin Ther Targets. 2018 Nov;22(11):941-953. doi: 10.1080/14728222.2018.1538356. Epub 2018 Oct 24.

Abstract

Adipocytes, which represent a substantial part of the tumor microenvironment in breast cancer, secrete several adipokines that affect tumorigenesis, cancer progression, metastasis, and treatment resistance via multiple signaling pathways. Areas covered: In this review, we focus on the role of leptin, adiponectin, autotaxin, and interleukin-6 in breast cancer initiation, progression, metastasis, and drug response. Furthermore, we investigated adipokines as potential targets of breast cancer-specific drugs. Expert opinion: Adipokines and adipokine receptors are deregulated in breast cancer. Adipokines play various roles in breast cancer initiation, progression, metastasis, and drug response, hence, adipokine signaling could be an effective drug target. Several clinical trials are in progress to test the efficacy of adipokine targeting agents. However, adipokines also affect metabolic homeostasis; hence, the adverse effects of the targeted drug should be investigated and addressed.

Keywords: Adipokines; adiponectin; autotaxin; breast cancer; interleukin-6; leptin; target therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adipocytes / metabolism
  • Adipokines / metabolism*
  • Animals
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Female
  • Humans
  • Molecular Targeted Therapy
  • Neoplasm Metastasis
  • Signal Transduction / drug effects
  • Tumor Microenvironment

Substances

  • Adipokines
  • Antineoplastic Agents